Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528668 | 0.82 | MEN1 (0.66) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL29367470 | 0.81 | KMT2A (0.74) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL6524461 | 0.81 | KMT2A (0.74) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL29818694 | 0.76 | MEN1 (0.57) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL6922748 | 0.76 | KMT2A (0.66) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL31118970 | 0.76 | MEN1 (0.50) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL45682 | 0.76 | KDM4E (0.75) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL22833004 | 0.75 | MEN1 (0.56) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL8913992 | 0.74 | KMT2A (0.55) | KMT2AMEN1MAPTHTTGAA | |
| SCHEMBL13140583 | 0.74 | MEN1 (0.55) | KMT2AMEN1MAPTHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227793-A1 | COMPOSITIONS AND METHODS FOR GLYCAN SEQUENCING | NATIONAL SCIENCE FOUNDATION | 2014-08-14 | — | — | US | disclosed |
| US-20140227793-A1 | COMPOSITIONS AND METHODS FOR GLYCAN SEQUENCING | NATIONAL SCIENCE FOUNDATION | 2014-08-14 | — | — | US | disclosed |
| EP-2252595-B1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071766-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-4960889-A | CEPHALOSPORIN INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-02 | — | — | US | disclosed |
| US-4731443-A | 7-acylamino-3-vinylcephalosporanic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| EP-0244637-A1 | Starting compounds for 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-11-11 | — | — | EP | disclosed |
| EP-0030630-B1 | 7-ACYLAMINO-3-VINYLCEPHALOSPORANIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM; THEIR STARTING COMPOUNDS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-01 | — | — | EP | disclosed |
| US-4585860-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| US-4487927-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0123024-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| US-4409214-A | Including cefixime; antibiotics | FUJISAWA PHARMACEUTICAL, CO., LTD. (JP) | 1983-10-11 | — | — | US | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227793-A1 | COMPOSITIONS AND METHODS FOR GLYCAN SEQUENCING | ST3GAL3, OSTC, MLX | KMT2A 2660/4885MEN1 3121/4885MAPT 4529/4885 |
| US-20120264770-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | KMT2A 3857/4885MEN1 4621/4885MAPT 1094/4885 |
| US-20110053873-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | KMT2A 4022/4885MEN1 4536/4885MAPT 1054/4885 |
| US-20120172321-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | KMT2A 3857/4885MEN1 4621/4885MAPT 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.